Table 3.
Characteristics of the patients with breast cancer
| Number of patients | |
|---|---|
| Characteristics | n = 159 (%) |
| Stage at diagnosis | |
| I | 17 (11) |
| II | 50 (31) |
| III | 32 (20) |
| IV | 31 (20) |
| Unknown | 28 (17) |
| Subtype | |
| HR+ HER2- | 108 (68) |
| HR+ HER2+ | 20 (13) |
| HR- HER2+ | 9 (6) |
| HR- HER2- | 14 (9) |
| Unknown | 8 (5) |
| Perioperative chemotherapy | |
| Yes | 61 (38) |
| Anthracycline regimen | 11 (7) |
| Anthracycline + taxane regimen | 26 (16) |
| Other regimens | 24 (15) |
| No | 97 (61) |
| Unknown | 1 (1) |
| Adjuvant endocrine therapy | |
| Aromatase inhibitor | 39 (25) |
| Tamoxifen | 29 (19) |
| Ovarian function suppression | 22 (14) |
| None | 22 (14) |
| Unknown | 1 (1) |
| Prior treatment with zoledronic acid | |
| Yes | 39 (25) |
| No | 92 (60) |
| Unknown | 23 (15) |
| Number of denosumab doses | median 18 (range: 1–79) |
| More than 45 doses of denosumab | 15 (9) |